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INTRODUCTION 
Immune suppression is the inability to mount a normal 
immune response and can be artificially induced in several 
ways, which may be antigen-specific or nonspecific. Anti-
gen-specific suppression can be caused by an excess of 
specific.antibody or by paralysis induced by specific 
antigen. Nonspecific immune suppression can be brought 
about by the use of antilymphocyte or antiimmunoglobulin 
serum, cytotoxic drugs, adrenocortical hormones, X-irradiation 
or surgical removal of lymphoid organs (in particular, 
thymectomy). Depending on the method used, immune sup-
pression may affect primarily antibody-mediated immunity 
or cell-mediated immunity or .both. For example, surgical 
.removal of the thymus affects mainly cell-mediated func-
tions, whereas cytotoxic drugs have some effect on humeral 
and cellular immunity (Webb and Winkelstein, 1978). 
The present study was designed to develop a means of 
causing immunosuppression in the pig for use in studies on 
the pathogenesis of infectious diseases in this species. A 
primary criterion in the selection of an agent was its 
ability to caµse immune suppression without mortality. 
Thymectomy in the pig has been previously shown to suppress 
some in·vivo and in. vitro functions of cell-mediated im-
munity, without prolonging graft survival, and treatment 
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with antilymphocyte serum as well magnified the observed immune 
suppression (Binns et al., 1972). It.was decided not to 
use these two methods in the present study because of the 
poor degree of immunosuppression obtained by these workers, 
the expense and time involved in surgical manipulations 
and the variability inherent in the use of antilymphocyte 
sera (Bach, 1975). The cytotoxic drug cyclophosphamide (CY) 
was selected because it causes reproducible and well-
characterized immune :>uppression in many animal species 
(Bach, 1975). 
Cyclophosphamide acts as an alkylat:lng agent, causing 
damage to nucleic acids, including breaks in DNA strands, 
cross-links between DNA strands and cross-links between 
DNA and RNA or protein. Cyclophosphamide therefore pre-
vents mitosis and kills cells undergoing multiplication and 
cells with. a high rate of RNA or protein synthesis (Bach; 
1975). The alkylating activity is not present in CY itself, 
but is dependent on the' production of metabolites of CY by a 
microsomal enzyme system in the liver (Bach, 1975). 
Cyclophosphamide appears to be selectively cytotoxic 
for lymphocytes at intermediate doses (Petrov et al., 1971), 
but it does have some effect on all rapidly dividing tissues, 
such as bone marrow, gastrointestinal tract and hair follicles 
(Bach, 1975). 
In human medicine, CY is use.d as an immunosuppressant 
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in organ transplantation and treatment of immunologic disease 
(Webb and Winkelstein, 1978). Experimentally, CY has been 
used in numerous studies to elucidate some aspects of the 
immune response (for example Turk and Poulter, 1972b; 
Glaser, 1979; Ramshaw et al., 1977) as well as in the in-
vestigation of the pathogenesis of various bacterial and 
viral infections (see Literature Review) . 
A preliminary study on the effect of CY in the pig 
suggested that in this species CY causes depletion of 
lymphoid tissues; however, no attempt was made to determine 
a dosage schedule which caused immune. suppression without 
mortality, and no functional tests of the immune response 
were carried out (Anderson et al., 1974). In the present 
study it was considered necessary to develop ih the pig a 
nonlethal CY treatment regimen which produced maximal iinmune 
suppression with minimal effects on other tissues, and then 
to characterize further the effects of CY on the immune 
~ystem of the pig. 
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LITERATURE REVIEW 
Many techniques are available for investigating the 
immune response, and thus for characterizing the effects of 
immunosuppressive procedures. In this literature review, 
CY will be discussed in relation to its effect on some 
commonly investigated parameters. 
Cyclophosphamide Dosage and 
Toxicity 
A wide variety of doses of CY has been used to caµse 
immune suppression. Cyclophosphamide may be administered as 
a high dose in a single injection, or as a lower dose re-
peated sever.al times. Table 1 summariz.es the treatment 
schedules used experimentally in different species by a 
number of workers. The route of administration is usually 
intraperitoheal but the intramuscular, subcutaneous, intra-
venous and oral routes have occasionally been used (see 
Table. 1). 
The dosages of CY which produce toxicity vary with 
animal species, sex and presence of normal bacterial flora. 
Kovacs and Steinberg (1972) described 3 toxic' syndromes 
caused by CY ih mice. Single high doses (600 mg/kg) caused 
rapid death which was not prevented by bone marrow trans-
plantation. Lower single doses (400 mg/kg) caused leuko-
penia and death within 2 weeks and daily doses of 40 mg/kg 
Table l. Immunosuppressive doses of cyclophosphamide used in different species 
Species Dose of CY Route 
Number of 
Frequency Reference (mg/kg) treatments 
Mouse 100 s.c. l Ramshaw et al. (1977) --
150 i.p. l Maguire et al. (1979) 
300 i.p. l Turk and Poulter (1972a) 
400 i.p. 1 Stockman et al. (1973) --
10 s.c. 28 daily Renoux and Renoux (1980) 
300 i.p. 3 every 2 days Turk and Poulter (1972a) 
Guinea pig 150 i.p. l Winkelstein (1977) 
300 i.p. l Turk and Poulter (1972a) 
10 i.p. 7 daily Turk (1964) 
20 i.p. 14 daily Maguire and Steers (1963) 
50 i.p. 16 weekly Revell (1978) 
Rat 20 i. lit. 5 daily Santos and OWens (1966a) lJl 
60 i.rn. 2 daily Chakhava and Ruban (1979) 
180 i.m. 2 daily Chakhava and Ruban (1979) 
Chicken 70 i.p. 4 daily Sharma and Lee (1977) 
Ox 5 i. v. 10 every 2 days Carrier et al. (1979) --
Sheep 15 i.,v. 10 weekly Jun and Johnson (1979) 
Dog 3 oral 15 daily Putnam et al. (1975) --
Human 0.7 oral 30-750 ·daily Winkelstein et al. (1972) 
7 i. v. 7 '.daily Santos et al:-(1970) 
25 i.v. 3 daily Santos et al. (1970) --
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led to profound bone marrow depression, superinfection, 
wasting and death. The 2 latter syndromes could be pre-
vented by bone marrow transplantation. Turk and Poulter 
(1972a) observed that three injections of 300 mg/kg at 48 
hour intervals were "usually fatal" in mice. Dose-response 
curves for suppression of the antibody response and for 
mortality have been determined for CY in mice (Berenbaum 
and Brown, 1964). On the basis of these curves,Berenbaum 
and Brown calculated that the therapeutic index (the ratio 
of the 50%' lethal dose to the dose which causes 50% sup-
pression of the mean antibody response) was 11.0; a 50% 
lethal dose of 500 mg/kg was observed and the dose causing 
50% antibody suppression was 45 mg/kg: 
Cyclophosphamide causes toxicity at lower doses in 
rats than in mice. Going et al. (1970) reported a 17% 
mortality rate at i60 mg/kg in rats. Chakhava and Ruban 
(1979) observed deaths in conventionally-raised rats, but 
not in gnotobiotic rats, treated with single doses of 160-
180 mg/kg. Male mice appear to be more susceptible to the 
toxic effects of CY than female mice; 92% of males died 
after treatment with 400 mg/kg whereas 100% of females 
survived 500 mg/kg (Stockman et al. 1973). 
There are no published data relating CY dosage to 
toxicity· in pigs. 
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Effect of Cyclophosphamide oh Cells Involved.in the 
Immune Response 
Circulating leukocytes 
Although not strictly involved in the immune response, 
neutrophils will be considered here since they are im-
portant effectors of immune function. Cyclophosphamide 
causes depression of the total blood leukocyte count. 
Fried and Johnson (1968) reported a 67% depression of the 
tota~ leukocyte count in CY-treated mice. This depression 
is contributed to by a decrease in both circulating neutro-
phils and lymphocytes. The suppressive effect of CY on 
these cell populations has been reported in mice, guinea 
pigs (Turk and Poulter, 1972b), rats (Going et al., 1970), 
chickens. (Linna et al., 1972), cattle (Wagner et al., 
1976), pigs (Anderson et al., 1974) and humans (Winkelstein 
et al., 1972). 
Lympho'id tissues and· lymphocyte subpopulations 
~istopathological studies have demonstrated that CY 
depletes lymphocytes from lymphoid tissues, with a more 
dramatic.effect on B cells than on T cells. Linna et al. 
(1972) showed that CY treatment of newly hatched chickens 
caused almost complete disappearance of lymphocytes from 
the bursa of Fabricius, and irreversible destruction of the 
normal bursal architecture; lymphoid follicles (B-dependent 
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areas} were persistently absent from the spleen and cecal 
tonsils. The cortex of the thymus was initially depleted 
of lymphocytes; however,thymic morphology was completely 
restored within 12 days of cessation of treatment. Because 
of these differential effects the authors describe CY treat-
ment of newly hatched chickens as a method of "chemical 
bursectomy". , Rouse and Szenberg (1974) obtained similar 
results in chickens. In these experiments bursal regenera-
tion was, however, seen in some chickens and a transient 
depletion of lymphocytes in periarteriolar lymphoid sheaths 
{T-dependent areas) of the spleen was also described. 
Cyclophosphamide treatment of mice resulted in the 
complete absence of lymphocytes in the lymphoid follicles 
of the lymph nodes and spleen. The lymphocytes in the 
paracortical areas of the lymph nodes, however, were 
partially but never completely depleted and a considerable 
number of lymphocytes always remained in the periarteriolar 
sheaths of the spleen {Turk and Poulter, 1972a). Similar 
changes were observed in guinea pigs by the same authors. 
Thus, in this study CY caused the complete removal of 
lymphocytes from B-dependent areas and partial depletion 
of T-dependent areas in lymph nodes and spleen. In the same 
study CY caused a dramatic depletion of lymphocytes from the 
cortex of the thymus of both mice and guinea pigs, with a 
mild depletion from the medulla. Lymphocyte repopulation of 
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lymph nodes, spleen and thymus was evident in mice 7 days 
after CY treatment, however no lymph follicles were seen 
at this time (Turk and Poulter, 1972a). A similar pattern 
of lymphocyte depletion in the thymus and peripheral 
lymphoid tissues has been observed in cattle (Corrier et al ., 
1979) and in a prel i minary study in pigs (Ander son et al., 
1974). 
Various other methods have been used to investigate 
the effect of CY on T and B cell populations in lymphoid 
tissues. Bach and Dardenne (1972) examined the effect of the 
administration of thymus and or bone marrow cells on the 
ability of CY-treated mice to form antibodies to sheep 
erythrocytes. Antibody formation was suppressed in mice 
which received CY and could only be reconstituted with the 
in j ection of both thymus and bone marrow cells . These results 
do not provide any evidence for a preferential effect on 
B cells but they do suggest that CY depletes both T and B 
cells in peripheral lymphoid tissues. 
Poulter and Turk (1972) investigated the effect of 
CY on the percentage of lymphocytes carrying the 8- antigen 
(a T cell marker) in the lymph nodes and spleen of mice . 
It was observed that CY caused an increase in the proportion 
of T cells . This confirms the suggestion that CY can have a 
greater effect on B cells than T cells in peripheral lymphoid 
tissues. 
10 
The effect of single CY treatments on B and T lympho-
cytes in the spleen of the mouse was evaluated· by examining 
the presenc.e of surface-associated irnrnunoglobulins (a B 
.cell marker) ,. the electrophoretic mobility and the 
responsiveness to T and B' cell mitogens of spleen cell 
suspensions (Dumont, 1974). Both Band T cells were 
depleted but the B cell component was more dramatically 
affected and started to recover much later than the T 
cell component •. 
Winkelstein (1977) demonstrated a 60-70% depletion of 
both T and B cells (measured by rosetting with rabbit 
erythrocytes and by complement rosettes, respecti.vely) in 
guinea pig lY!llPh nodes. This is at variance with the obser-· 
vatioh o:E Turk and Poulter (1972a) that on histological 
examination B cell depletion in.guinea pig lymph nodes was 
much greater than T cell depletion. Perhaps this can be 
explained by a difference in dose rates since Winkelstein 
used half the single dose· used by Turk and Poulter. 
The effect of CY on T and B lymphocyte counts in 
peripheral blood has been investigated, with apparently 
confl·icting results. Revell (1978) reported that long-term 
CY treatment in guinea pigs caused a depletion of circulating 
B cells with no significant depletion of circulating T 
' cells. Winkelstein (1977) showed, however, that a single 
CY treatment in guinea pigs depleted both T and B lymphocytes 
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by 60-70%, with a more rapid recovery of T cells than B 
cells. The difference in results could be d.ue to the dif-
ference in dosage schedules. Revell did not carry out T 
and B cell determinations until 7 days after the last CY 
administration, whereas winkelstein observed that normal 
T cell counts were restored by 8 days after treatment and 
B cell counts were depressed until 14 days after treatment. 
This probably accounts for the apparent lack of T cell 
depletion in Reve11·•s study. Anderson et al. (1974) 
observed a decrease in B cell percentages and an increase 
in T cell percentages in peripheral blood of CY-treated 
pigs. These results are difficult to evaluate since abso-
lut·e cell counts were not presented and the T cell marker 
used (rosette formation with untreated sheep erythrocytes) 
has since been shown to be inadequate for T cell enumeration 
in pigs (Binns, 1978). 
Thus, it seems apparent that under most experimental 
conditions CY exerts a greater depressive effect on B lympho-
cyte populations than on T lymphocyte populations. Reasons 
for this selective effect have been speculated upon by 
several workers.. Cyclophosphamide destroys cells ·under-
going DNA synthesis, and therefore has a preferential ef-
feet on rapidly proliferating tissues (Bach, 1975). Thus, 
Lagrange et al. (1974) and Turk and Poult.0>r (1972b) have 
' 
hypothesized that CY selectively dest.t·oy3 B cells because 
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they are short-lived and undergoing more rapid proliferation 
than the long-lived T lymphocytes. Indeed, Miller and Cole 
(1967) demonstrated by using tritiated thymidine labeling· 
tha.t in rat lymph nodes long-lived cells were resistant 
to long-term CY treatment. Also, Turk and Poulter (1972b) 
examined the effect of CY on mouse lymphoid tissues labelled 
with radioactive iododeoxyurtdine (which labels dividing 
.cells) and sodium chromate (which labels nondividing and 
dividing cells). CY depleted the rapidly dividing lympho-
cytes without affecting the nondividing population. Dumont 
(1974) proposed that T cells may have a greater qapacity 
for repairing the DNA lesions induced by CY's alkylating 
activity: cells which could repair DNA between mitoses 
would be protected from the cytotoxic effects of CY arid thus 
J.3 cells.would be more dramatically affected than T cells. 
Bach (1975) has suggested that CY has a greater effect on 
B cells because t.hey have a higher metabolic activity than 
T cells and CY not only affects cells undergoing mitosis 
but also cells with a high rate of RNA or protein synthesis. 
It seems likely that all these suggested mechanisms may 
play a part in the differential effect of CY on B and T 
cell.populations. 
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Macrophages 
Conflicting results ·have been obtained on the effect 
of CY on macrophage populations. One day after the comple-
tion of a course of 8 daily CY injections, macrophage numbers 
in induced peritoneal exudates from guinea pigs were sig-
nificantly depressed (Winkelstein, 1973). However, 18 days 
after receiving a single injection of CY, guinea pigs had 
normal peritoneal macrophage numbers (Jokipii et al., 1979). · 
In the latter study a depression may have been seen if testing 
had been carried out earlier. 
Effect of Cyclophosphamide on Functions of 
Antibody-Mediated Immunity 
Antibody production 
Cyclophosphamide has been shown to suppress antibody 
formation in mice (Berenbaum and. Brown, 1964; Stockman et a,l., 
1973), rats (Going et al., 1970; Santos and OWens, 1966a), 
guinea pigs (Turk and Parker, 1973), chickens (Lerman and 
Weidanz, 1970; Linna et al., 1972), dogs (Putnam et al., 
1975), cattle (Corrier et al., 1979) and humans (Santos 
et al., 1970). The suppression is seen as a depression of 
nonspecific.serum immunoglobulins, both IgG and IgM (Lerman 
and Weidanz, 1970; Corrier et al., 1979) and also as a sup-
pression of antibodies to specific antigens. Such antigens 
include sheep, horse•and chicken erythrocytes (Santos and 
I 
I 
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owens, 1966a; Rouse and Szenberg, 1974; Corrier et al., 
1979), protein antigens such as ovalbumin, bovine serum 
albumin and keyhole limpet hemocyanin (Turk anp. Parker, 
1973; Lerman and weidanz, 1970; Stockman et al., 1973), 
bacterial antigens such as Salmonella and Brucella (Lerman 
and Weidanz, 1970; Linna et al., 1972) and tumor antigens 
(Phillips, 1970). 
The dose of CY is important in determining whether 
suppression of antibody formation occurs, and the degree of 
suppression. Berenbaum and Brown (1964) determined a dose 
response curve for CY with respect to the formation of anti-
bodies to Salmonella typhi H antigens in mice. The curve 
was exponential and single injections of 20 mg/kg administered 
2 days after immunization had no effect on the antibody 
response whereas doses of 50 mg/kg and greater reduced the 
antibody titer to below the lowest measurable level. 
Kerckhaert et al. (1977) showed that O.oses of 100 mg/kg of 
CY were.required to suppress formation of, antibodies to 
sheep red blood cells (SRBC) in mice. In this case the drug 
was administered 8 hours before immunization; t~us, the dif-
ference in dose effect in the two studies may result from 
the difference in timing;· differences in the antigen and 
the genetic .background of the mice may also account for the 
discrepancy. Seventy percent of chickens which received 
3 daily doses of 100 mg/kg of CY showed a response to killed 
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Brucella abortus organisms, whereas no chickens which re-
ceived 3 doses of 200 mg/kg responded (Rouse and Szenberg, 
1974). It is interesting to note that in mice antibody 
suppression occurred at a dose well below that which causes 
death due to toxicity (Berenbaum and Brown, 1964), whereas 
in chickens antibody suppression only occurred with lethal 
doses (Rouse and Szenberg, 1974). 
The suppressive effect of CY on antibody responses 
also depends on whether single or multiple dosage regimens 
are used and the timing of CY administration in relation to 
antigen administration. Single doses of 50 to 125 mg/kg in 
humans did not suppress the mean antibody titer to Vi anti-
gen from Escherichia coli, however 7 daily doses of 7 mg/kg 
completely eliminated the response (Santos et al., 1970). 
In both cases the antigen was administered 4 hours after the 
first dose of CY. In man the active metabolites of CY fall 
to relatively low levels in serum within 4 hours of 
administration 0£ CY (Brock et al., 1971). Thus, perhaps 
single high doses administered before antigen sensitization 
do not remain active for long enough to exert a significant 
effect on B cell differentiation and antibody formation, 
whereas the continual replacement of CY with daily.doses may 
allow this. This suggestion is supported by the observation 
that in mice single nonlethal doses of CY, administered 2 
days after antigen sensitization, can eliminate the anti-
16 
body response (Berenbaum and Brown, 1964). Presumably at 
this time CY is able to destroy the rapidly dividing, sensi-
tized B cell' population. Santos et al. (1970) treated 
humans with a variety of multiple low dose (7 to 25 mg/kg) 
CY schedules and compared the effect of Pasteurella 
tularensis vaccine administered 3 days before the first drug 
dose with that of Vi antigen administered 4 hours after 
the last drug dose. Most patients responded well to Vi 
.antigen but in all cases there was no detectable serum titre 
to P. tularensis. Thus, in humans, the response to antigens 
administered after cessation of CY treatment is poorly sup-
pressed. In con_trast, chickens treated with 3 daily doses 
of CY at hatching remained unresponsive to antigens ad..: 
ministered at 6 weeks of age (Lerman and Weidanz, 1970). 
It must be noted that at least 50% mortality resulted from 
the CY doses used in this study. 
Santos and OWens (1·966a) examined· the effect of immuni-
zation ()f rats with SRBC at various times in relation to a 
5-day course of injections of CY. Antigen was administered 
5 days or 2 days before commencement of CY treatment, 
or 2 days after completion of CY treatment. In all cases 
the formation of specific antibodies was suppressed, how-
ever the different schedules had different effects on specific 
IgM and IgG. Immunization 5 days before CY treatment caused 
a prolongation, of IgM production and a premature drop in IgG. 
17 
When the antigen was administered 2 days before CY treat-
ment, there was only a short IgM response with an absence of 
IgG. Immunization 2 days after cessation of CY treatment 
also resulted in a lack of IgG, but IgM pro.duction was de-
layed. Thus, if antigen is administered up to several days 
before CY treatment and in certain situations after CY 
treatment, antibody formation is suppressed. Antibody pro-
auction to antigens administered on the same day as a single 
CY treatment are usually suppressed in mice (Lagrange et aL , --
1974; Frisch and Davies, 1966; Phillips, 1970). Immuniza-
tion at some stage during a course of multiple CY administra-
tipns also has been commonly. used to suppress the humoral 
immµne response in experimental situations, for example in 
dogs (Putnam et al •. , 1975) and· cattle (Corrier et al., 1979). 
Cyclophosphamide has a differential effect on dif-
ferent antibody classes. This has been demonstrated by 
Santos and OWens (1966a) as described above. Phillips (1970) 
treated mice carrying transplantable tumors with CY and 
examined antibody production by the regional lymph nodes. 
Cyclophosphamide eliminated a normal IgGl response and 
delayed the IgG2 and IgM responses by 6 days. The results 
of these two studies suggest that CY has a more marked effect 
on IgG than on IgM. Chickens treated with CY at hatching 
showed severe depletion of both IgG and IgM in serum until 
at least 11 weeks of age (Lerman and Weidanz, 1970); some 
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birds which survived toxic doses· of CY had no detectable 
levels of either class of immunoglobulin. 
Cyclophosphamide may completely eliminate the anti-
body response or may simply lower the titer or delay a 
normal response. Which of these possible outcomes occurs 
is dependent on timing and dosage. The timing effect was 
demonstrated by Going et al. (1970). Rats treated with 2 CY 
injections 24 hours apart showed no detectable response to 
SRBC administered 3 days before or 4 days after the first 
CY injection whereas when the antigen was administered at 
various intervals up to 38 days after CY treatment, succes-
sive increases in the response.were seen, although at no 
stage were the titers as high as in controls. The dose ef-
feet was demonstrated well in mice by the work of Berenbaum 
and Brown (1964). Intermediate Cy doses lowered the anti-
body titre to ~· typhi and higher doses completely elimi-
nated the response.· A single dose of 100 mg/kg of Cy in 
mice served only to delay a normal antibody response to 
SRBC; 5 days after immunization antibody levels were de-
pressed but at 7 days they were normal (Kerckhaert et al., 
1977). 
Most of the studies which have been discussed here 
demonstrate the suppression of primary responses. Cyclo-
phosphamide may be equally efficient at suppressing 
secondary responses.· Linna et al. (1972) showed that CY 
' _. 
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administered before primary immunization depressed antibody 
formation in response to primary and secondary stimulation 
in chickens. Putnam et al. (1975) showed that in dogs CY 
treatment commencing at the time of secondary immunization 
suppressed the secondary response. 
Immunological tolerance 
Several workers have described the induction of im-
munological tolerance by CY. 
Frisch and Davies (1966) treated mice with CY 24 hours 
after immunization with human erythrocytes. The mice were 
unable to respond to a second dose of human erythrocytes 
administered at a time when they had recovered their normal 
responsiveness to SRBC. In this study the mice .remained 
refractory to stimulation with human erythrocytes for 10 
days after the primary stimulus. Guinea pigs treated with 
egg albumin during a 14-day course of CY were tolerant 
to this antigen at 5-1/2 weeks after primary immunization, 
which was the only time of testing (Maguire and Steers, 
1963). Many and Schwartz (1970) showed that the repeated 
administration of antigen could lead to the maintenance of 
CY-induced tolerance for as long as 9 months in some mice. 
The likelihood that CY will induce toler.ance is greater 
the higher the dose of CY (Frisch and Davies, 1966) and the 
higher the dose of antigen (Aisenberg, 1967). 
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Aisenberg (1967) suggested that CY-induced tolerance 
is caused by antigenic stimulation in the presence of 
CY-inhibited DNA synthesis and mitosis, leading to the elimi-
nation of the specific immunological clone. In contrast, 
Ramshaw et al. (1977) obtained results suggesting that the 
maintenance of the unresponsive state is due to the activa-
tion of suppressor T cells by CY. 
Response to B cell mitogens 
The ability of lymphocytes to undergo transformation 
in response to. mitogenic substances is a commonly used test 
of the functional integrity of these cells. Lymphocyte 
transformation is usually measured by the uptake, of tritiated 
thymidine by lymphocytes in culture. 
Cyclophosphamide treatment of mice completely abolished 
the in vitro proliferative response of their spleen cells to 
bacter'ial lipopolysaccharide, which is a B cell mitogen 
(Dumont, 1974). Stockman et al. (1973) described pokeweed 
mitogen (PWM) as a B cell mitogen but it is now generally 
considered to be mitogenic for both T and B cells (Douglas, 
1978). Thus,Stockman's results demonstrating that spleen 
cells from CY-treated mice were unresponsive to PWM are 
difficult to interpret. However; the fact that the response 
to the T cell mitogen phytohaemagglutinin recovered more 
quickly than the response to PWM, supports the authors' 
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conclusion that B .cell function was suppressed. 
Effect of Cyclophosphamide on Functions of 
Cell-Mediated Immunity 
Delayed hypersensitivity 
Contact sensitivity will be included in the discussion 
on delayed hypersensitivity. Some authors consider contact 
sensitivity to be a type of delayed hypersensitivity reac-
tion (Fudenberg et al., 1978) whereas others consider the 
two reactions to be distinct (Jokipii et al., 1979). 
Cyclophosphamide suppresses delayed hypersensitivity 
reactions under certain experimental conditions. When 
administered after sensitization, CY suppressed the formation 
of contact sensitivity to oxazolone and picryl chloride in 
guinea pigs (Turk and Stone, 1963; Turk, 1964)'. Cycle-
phosphamide administered simultaneously with tuberculin 
purified protein derivative (PPD) prevented the cutaneous 
response of guinea pigs (Winkelstein, 1973). Turk (1964) 
s~owed that the depression of contact reactivity in the 
guinea pig was part~y but not entirely due to an anti-
inflammatory action of CY. Turk and Stone (1963) associated 
the CY-induced blockage of contact sensitivity in the guinea 
pig with the inhibition of development of large pyronino-
philic cells in local lymph nodes during the early phase 
of sensitization. In the light of more recently acquired 
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knowledge, the suppression of delayed hypersensitivity by 
CY can probably be attributed to ,the toxic effect of CY on 
repiicating T cells after sensitization. 
In contrast, the administration of CY before sensitiza-
tion· has been shown to prolong and intensify delayed hyper-
sensitivity reactions (Turk et al., 1972). Turk et al. 
(1972) showed that in CY-treated guinea pigs enhanced contact 
sensitivity to dinitrofluorobenzene (DNFB) occurred in the 
presence of a suppressed antibody response to DNFB and in 
the presence of apparently normal T cell areas in. local lymph 
nodes. The CY effect was partially reproduced by splenectomy. 
These authors cdncluded that CY blocks a B lymphocyte response 
which modulates the normal development of delayed hyper-
sensitivity. Lagrange et al. (1974) showed that, with in-
creasing doses of immunogen, the antibody response to SRBC 
in mice increased, whereas the delayed response decreased. 
Moreover, CY administered before sensitization enhanced the 
delayed response. Thus, these workers also suggested that 
CY eliminates a modulating B cell response. 
B cell deficient mice pro~uced a normal contact 
sensitivity reaction which could be enhanced by CY to the 
same degree as the reaction of normal mice (Maguire et al., 
1979). This suggests that CY does not remove suppressor B 
cells. Cell transfer experiments on CY-treated mice sensi-
tized with· methylated human serum albumin provided evidence 
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that CY eliminates suppressor T cells which normally regu-
late delayed hypersensitivity (Mitsuoka et al., 1979). 
Mitsuoka et al. (1979) suggested that two T cell subpopu-
lations, with different recovery rates after CY treatment, 
are involved in delayed hypersensitivity responses. They 
proposed that effector T cells recover more rapidly than 
suppressor T cells. Cyclophosphamide treatment before anti-
gen sensitization could result in the presence of recovered 
effector cells and the absence of suppressors at the time 
of sensitization; thus an enhanced response would occur. 
·with CY treatment after sensitization both T cell popula-
tions would be affected simultaneously and a reduced response 
would occur. This seems· to be the most plausible explana-
tion for enhancement of delayed reactions by CY, since the 
results of Magµire et al. (1979) and Mitsuoka et al. (1979) 
are more concrete than the circumstantial evidence used to 
support the argument for the removal of B cell mediated 
suppression. 
Conflicting results have been obtained with sensitiza-
tion to PPD. Cyclophosphamide pretreatment enhanced delayed 
hypersensitivity to PPD in cattle (Corrier et al., 1979) 
but depressed the reaction in guinea pigs (Jokipii et al., 
1979). Since the t~eatment schedule used by Jokipii et al. 
was the same as that used by Turk et al. (1972) to enhance 
contact sensitivity in guinea pigs, no explanation for this 
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inconsistency can be provided. 
Graft rejection 
Cyclophosphamide treatment of skin graft recipients 
prolongs graft survival. Cyclophosphamide prolonged the 
survival of skin grafts in rats by several days. The effect 
was greater when grafts were between rats compatible at the 
Ag-B histocompatibility locus than when grafts were between 
incompatible rats (Silvers et al., 1967). In chickens, CY 
administered at the time of hatching prolonged the survival 
.of allogenic skin grafts by more than 11 days. The CY 
effect was seen if grafts were applied at 1 week of age 
but not at 3 weeks (Rouse and Szenberg, 1974), and the dosage 
us.ed was lethal for some birds. 
Cyclophosphamide has a greater effect on the survival 
of renal allografts than.skin allografts in rats and the ef-
feet is dependent on CY dosage. single treatments or 3 
weekly_ treatments commencing at the time of grafting usually 
only prolonged renal graft survival by a few days. However, 
21 9aily treatments commencing at the time of grafting pro-. . 
longed graft survival by more than 150 days (Kawabe et al., 
1972). In contrast, renal allograft survival was not pro-
longed in dogs which received daily treatments of 2 or 3 
mg/kg of CY (Putnam et al., 1975). Perhaps a higher dose 
than this is required for graft survival in the dog. 
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Santos et al. (1970) described a CY treatment protocol 
which allowed the establishment of bone marrow grafts in 
humans. The protocol involved.the induction of immune-
logical tolerance to the donor antigens. Donor antigen 
in the form of whole blood was administered 24 hours be-
fore commencement of a 4-day course of CY; donor marrow 
was administered 24 hours after the final CY treatment. 
Although_ in this case graft survival may have been due to 
tolerance,_it is thought that CY-induced prolongation of 
graft survival is_ usually due to a nonspecific suppression 
of cell-mediated immunity. For instance, in the study of 
Kawabe et al. (1972), rats with surviving renal allografts 
were probably not tolerant to donor antigens since they 
rejected normally donor skin which was applied 60 days after 
renal grafting. 
Graft versus host reactions 
Graft versus host reactions are suppressed by CY in 
rats. Santos and OWens (1966b) demonstrated that CY treat-
ment of the recipients of transplanted spleen cells sup-
pressed the graft'versus host reaction. Peripheral blood 
from CY-treated chickens had a reduc_ed ability to mount a 
graft versus host reaction in chicken embryos (Lerman and 
Weidanz, 1970; Rouse and Szenberg, 1974). 
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Tumor immunity 
Cyclophosphamide may affect. the ability of an animal 
to mount a cytotoxic response to tumors. Fass and Fefer 
(1972) inoculated mice with lymphoma cells and investigated 
the .in vitro cytotoxicity of their spleen cells to the tumor 
cells. If .the mice were treated with CY l day after lymphoma 
inoculation, the cytotoxic response was depressed, whereas 
CY administered l day prior to tumor inoculation enhanced the 
response. Cyclophosphamide treatment before tumor administra-
tion also enhanced the response of mouse spleen cells to 
transplantable SV40-induced sarcoma, as measured by a tumor 
cell neutralization assay (Glaser, 1979). The transfer of 
normal T cells to CY-treated mice abolished the CY-induced 
augmentation of immune.responsiveness, therefore Glaser 
post~lated the existence 6f CY-sensitive T cells which normal-
ly suppress effector T cells against SV40-induced sarcomas. 
These results are similar to those obtained by Mitsuoka 
et. al. (1979) who provided evidence that another function 
of cell-mediated immunity, delayed hypersensitivity, is also 
modulated by a CY-sensitive suppressor T cell population. 
Functional capacity of T lymphocyt·es 
In vivo administration of CY induces a decrease in the 
in vitro response of the surviving spleen, lymph node or 
blood lymphocytes to the T cell mitogens phytohaemagglutinin 
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(PHA) and concanavalin A (con A). This effect has been 
shown in mice (Stockman et al., 1973.; Renoux and Renoux,. 
1980), guinea pigs (Winkelstein, 1973), chickens (Sharma· 
and Lee, 1977), sheep (Jun, and Johnson, 1979) and humans 
(Winkelstein et al., 1972). Active CY metabolites from the 
serum of CY-treated guinea pigs have also been shown to 
suppress the PHA response when incubated with blood· lympho-
cytes from normal guinea pigs. (Balow et al., 1977). As 
dis·cussed previously,· the response to the B and T cell mitogen 
PWM was suppressed by CY for longer than the PHA response, 
suggesting a more prolonged effect on B cell function than 
on T cell function·(stockman et al., 1973). Winkelstein 
et al. (1972) att.ributed the decreased PHA responsiveness 
to a "functional sterilization" of lymphocytes, as mani~ 
fested by chromosomal deletions· and changes in the struc-
tural integrity of chromosomes in lymphocytes from CY-
.treated patiEmts. 
·Elaboration of macrophage inhibition factor (MIF) by 
lymph node cells from CY-treated guinea pigs was depressed 
(Winkelstein, 1973). Normal guinea pig lymphocytes, incu~ 
bat.ed with active CY metabolites in serum from CY-treated 
guinea pigs, w~re also deficient in MIF proµuction, (Balow 
et al., 1977). Incubation of normal guinea pig lymphocytes 
with active CY metabolites caused a transient suppression of 
·in vitro antibody-dependent and mitogen-induced cellular 
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cytotoxicity reactions against chicken erythrocytes (Balow 
et al., 1977). 
Thus, CY probably not only exerts its effects on the 
immune system by the depletion of lymphocyte populations., 
but also by the depression of the functional integrity of 
surviving lymphocytes. 
Effect of Cyclophosphamide on the Pat~ogenesis 
of Bacterial and Viral Infections 
Cyclophosphamide has been widely used to study the 
pathogenesis of infectious diseases. The pathogenic ef-
fects of infectious organisms are usually potentiated by 
CY. 
Cyclophosphamide caused an increase in the mortality 
of mice due to infection with Pseu:domonas· aeru:ginosa, in 
association with a marked increase in bacterial numbers in 
the liver, spleen and .kidneys of infected mice (Harada 
et al., 1979). Passively transferred immunity to Listeria 
monocytogenes, as determined by suppression of bacterial 
growth in liver and spleen, was prevented by CY treatment of 
mice which were the recipients of spleen cells from immune 
mice (Tripathy and Mackaness, 1969). 
Cyclophosphamide treatment often converts normally 
nonfatal virus infections to fatal infections. Cyclo-
phosphamide increased the mortality of mice .due to West Nile 
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virus (Nathanson and Cole, 1971) and Coxsackie B3 virus 
(Rager-Zisman and Allison, 1973) from 0% to 100%, and that 
due to systemic vaccinia inf.ection (Worthington et al., 
1972) from 10% to 94%. In all these instances CY increased 
the titer of viremia. Virus titers in many tissues of the 
Coxsackie virus infected mice and in the brains of the West 
Nile virus infected mice were also increased by CY. The 
CY-induced increase in mortality due to vaccinia and Cox-
sackie infection was associated with a depression of serum 
antibody levels to these viruses. Transfer of specific 
antisera, at the time when antibody responses became de-
tectable in virus-infected control animals, protected CY-
treated animals against mortality (Worthington et al., 
1972; Rager-Zisman and Allison, 1973). The level of viremia 
in chronic lactic dehydrogenase virus infections of mice 
was increased by CY treatment, once again in association 
with depressed antibody levels (DuBuy et al., 1971). - Pre-
treatment with CY prevented human diploid cell strain 
rabies vaccine from protecting against rabies infection in 
mice, in the presence of a ~ormal delayed hypersensitivity 
J:"esponse ·.and a depressed antibody response (Turner, 1979). 
Thus, CY has peen useful in investigating the role of anti-
body-mediated immunity in the control of several systemic 
virus infections. 
Smida and Smidova (1978) investigated the effect of 
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CY in chickens infected with avian sarcoma virus. CY in-
creased the mortality and incidence of progressive tumor 
growth. The authors considered these results to be evi-
dence for depression of cell-mediated immunity by CY. 
Mayo et al. (1977) showed that latent murine cytomegalo-
virus infections could be reactivated by CY, suggesting 
an involvement of the immune system in latent cytomega-
lovirus infections. 
Cyclophosphamide does not always exacerbate the effect 
of virus infections. Cyclophosphamide has been shown to 
prevent disease caused by visna virus in sheep (Nathanson 
et al., 1976) and lymphocytic choriomeningitis virus in mice 
(Cole et al., 1971) without preventing brain infection, thus 
helping to elucidate the immunopathologic nature of these 
two diseases. 
It is apparent from this review of the literature that 
CY has a wide range of effects on the immune system. Cyclo-
phosphamide depletes lymphocyte populations and depresses 
lymphocyte functions, with a greater effect on B cells than 
on T cells. This selective effect is probably due to dif-
ferent rates of metabolism, replication and DNA repair 
between B and T lymphocytes. Cyclophosphamide suppresses 
antibody-mediated immunity and may enhance or suppress cell-
mediated immunity; enhancement of cell-mediated immunity 
is probably due to a·lesser effect on suppressor T cells than 
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on other T cell subpopulations. Only a brief report has 
been published on the effect of CY in the pig (Anderson 
et al., 1974)1 this work suggested that CY has an effect 
on porcine lymphocyte populations similar to that seen in 
other species, however no tests of immune function or 
determinations of dose effects were presented. The present 
study was undertak.en in order to characterize more fully 
the effects of CY on the ·immune system of the pig. 
, 
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MATERIALS AND METHODS 
Animals 
One-week-old gnotobiotic Yorkshire pigs, one-week-old 
naturally farrowed Yorkshire pigs, six-week-old naturally 
farrowed Yorkshire pigs, ten-week-old naturally farrowed 
Berkshire pigs and ten-week-old naturally farrowed Yorkshire 
pigs were used in different experiments, as noted in the 
Results section. The gnotobiotic pigs were maintained 
under sterile conditions in isolators for the duration of 
the experiment (Waxler et al., 1966). Naturally farrowed 
pigs were raised conventionally and fed commercial rations. 
The great deal of variability in types of pigs used in dif-
ferent experiments was necessitated by the cost and avail-
ability of animals. 
Antibiotic Treatment of 
Animals 
In experiments 4 and 5 all treated and control pigs 
received 6 intramuscular injections of 200,000 units of 
penicillin G procaine and 0.25g dihydrostreptomycin1 
per 5 kg body weight. The injections were administered 
simultaneously with the first CY treatment and at 2-day 
intervals thereafter. 
1 Med-Tech Inc., Elwood, Kansas. 
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Collection of Peripheral 
Blood 
In experiments where naturally farrowed pigs were used, 
all bleeding and injection sites were shaved and swabbed 
with 2% tincture of iodine. Blood was collected from the 
. 1 .. cranial vena cava into evacuated glass tubes containing 
EDTA (1.4 g/ml blood) for complete blood counts, evacuated 
tubes1 containing heparin (14.3 units/ml blood) for T and B 
cell assays and evacuated serum separation tubes1 for 
titration of antibodies to SRBC and porcine parvovirus 
(PPV) • 
Cyclophosphamide Treatment 
of Animals 
Cyclophosphamide2 was dissolved in distilled water at a 
concentration of 100 mg/ml and passed through a .22µ filter. 
All treatments were administered intraperitoneally at the 
doses indicated in the Results section. 
Antigen Administration 
Sheep blood was collected by sterile venipuncture into. 
an equal volume of Alsever's solution. The SRBC were washed 
3 times in sterile phosphate-buffered saline (PBS) by 
1vacutainer, Becton-Dickinson, Rutherford, New Jersey. 
2
Polysciences Inc., Warrington, Pennsylvania. 
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centrifugation at 400 x g for 10 minutes. The buffy coat 
was aspirated and the SRBC made up to a 20% suspension in 
sterile PBS. Animals were immunized by intravenous in-
jection of 1 ml/kg of SRBC suspension. 
Inactivated PPV vaccine was prepared by a modification 
. of the method of Mengeling et al. (1979). Primary monolayer 
cultures of fetal porcine kidney (FPK) cells were sub-
cultured in 250 ml flasks at a ratio of 1:2 and inoculated 
simultaneously with about 108 cell culture infective doses50 
(CCID50 J of strain NADL-2 of PPV. After incubation for 3 
days at 37°C the cultures were frozen and thawed 3 times. 
The virus was inactivated by continuous stirring of infective 
medium and cell debris with a 0.3% volume of acetylethylene-
imine for 4 hours at 37°C. Aliquots we.re collected before 
and after inactivation to test for viral infectivity and 
hemagglutinating activity. The vaccine was dialyzed with 
Eagle's balanced salt solution to remove acetylethyleneimine, 
then tested for infectivity by titration of cytopathic ef-
fects in FPK monolayers in Leighton tubes. The vaccine 
contained 108 ccro50 of PPV/0.2 ml before inactivation, and 
0 CCID50;o.2 ml after inactivation. Hemagglutinating 
activity was determined by a tube agglutination test using 
guinea pig erythrocytes (Mengeling, 1972); the vaccine con-
tained 1,024 hemagglutinating units/ml before and after 
inactivation. Animals received a single intramuscular 
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injection of 5 ml of vaccine. 
Blood Counts 
Total leukocyte counts were determined using an 
l electronic cell counter . The accuracy of this method was 
investigated by obtaining 10 estimates of the total leuko-
cyte count for a single blood sample. The range of 10. 
values was 8,145-8,358 leukocytes/cu mm,. with a mean of 
8,245 and standard deviation 6f 64. 
Differential white blood cell counts were carried out 
on smears stained with a commercial differential stain2 . 
The percentage.of each cell type was calculated after counting 
100 cells oh each of 2 smears from each blood sample. The 
results obtained for estimates of the differential count, 
from 10 smears of a single blood sample are presented i~ 
T~ble 2. The total lymphocyte, neutrophil and monocyte 
counts were obtained by multiplying the total leukocyte 
count by the relevant percentage value. An animal was 
considered to have leukopenia, neutropenia or lymphopenia 
if the relevant cell count was significantly (p < .01) lower 
than the control value, as determined by the Student's t test. 
1coulter Counter Model z, Coulter Electrpnics Inc., 
Hialeah, Florida • 
. 2'. Diff-Quik, Harleco, Gibbstown, New Jersey. 
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Table 2. Range, mean and standard deviation of ten estimat~s 
of the differential white blood cell count from a 
single blood sample 
Range Mean Standard deviation 
% Segmented 
neutrophils 31-43 38.6 3.6 
% Band 
neutrophils 0-2 0.7 0.8 
% Lymphocytes 44-55 50.0 3.5 
% Monocytes 3-6 4.2 1.2 
% Eosinophils 4-9 6.1 1.8 
% Basophils 0-2 0.4 0.7 
Antibody Titration 
Anti-SRBCantibodies in serum were measured by a 
microtiter hemagglutination technique similar to that 
described by Reyero et.al. (1979). Sera were heated at 
·56 °C for 30 minutes, then placed in a 96-well round-bottom 
. . 1 1 microtiter p ate . Two-fold serial dilutions were made in 
PBS, using a microtiter dilution apparatus with 50 µl micro-
diluters2. To each, well 50 µl of a 0.5% suspension of 
thrice-washed SRBC in PBS were added. The plates were 
1
Titertek, Linbro Scientific Co. Inc., Hamden, Conn. 
2cooke Engineering Co., Alexandria, Virginia. 
37 
incubated for 90 minutes at room temperature before reading. 
Antibody titers are expressed as the reciprocal of the final 
serum dilution that caused hemagglutination. Each test 
serum was titrated in duplicate. Positive and negative 
control sera of .known titers were used each time the test 
was carried out. Titers of 32 and 0 were consistently 
obtained with 10 repeat titrations of the positive and 
negative controls, respectively. 
Ant.ibodies to PPV in serum were titrated by a .hemagglu-
tination inhibition technique, as described by Mengeling 
(1972.). Heat-inactivated (56°C, 30 minutes) serum (0.5 
ml) was.adsorbed with 0.5.ml of a 50% suspension of guinea 
pig· erythrocytes and 0.05 g of kaolin for· 30 minutes at 
room temperature then centrifuged at 1,000 x g for 15 
minutes. An initial 5-fold dilution and serial 2-fold 
dilutions of the supernatant serum were made in PBS. Each 
dilution of serum (0.25 ml) was mixed with 4 hemagglutinating · 
units of PPV (0.25 ml) and incubated at room temperature for 
30 minutes. An aliquot of 0.5 ml of 0.5% guinea pig 
erythrocytes was added to· each virus-serum mixture. These 
mixtures were.allowed to stand for 90 minutes then examined 
for· inhibition of 'hemagglutination. 
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Isolation of Peripheral Blood 
Lymphocytes 
Lymphocytes were isolated from peripheral blood ac-
cording to the method ,described by Paul et al .. (1979). Ten 
ml of heparinized blood was added to 20 ml of 0.85% NaCl. 
Fifteen ml of diluted blood was layered onto 4 ml of 
Ficoll-diatrizoate1 (specific gravity 1.08) in a 1.6 x 15 
cm glass tube. After centrifugation at 400 x g for 25 
miftute.s, the lymphocyte-rich layer was withdrawn and placed 
in 40 ml Hanks' balanced salt solution (HBSS). The cells 
were washed 3 times in HBSS by centrifugation at 400 x g 
for 10 minutes, then resuspended in HBSS to a concentration 
of 10 7 cells/ml. 
The leukocyte fraction obtained by this method is not 
composed ~n.tirely of lymphocytes, but contains a small per-
centage of contaminating cells (mostly monocytes with some 
polymorphonuclear cells). Estimates of 2-7% (Salmon, 1979) 
and 26% (Shimizu et al., 1976) have been obtained for the 
percentage of contaminating cells, as determined by endo-
genous peroxidase staining. Also, a percentage of lympho-
cytes do not react with either the Tor B cell marker and. 
are consid~red to be "null lymphocytes". Salmon (1979) has 
obtained an estimate of 15% null lymphocytes, but this is 
1
Ficoll-Paque, Pharmacia Fine Chemicals, Piscataway, 
New Jersey. 
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not corrected for contaminating cells. 
Since the percentage of contaminating cells in the 
lymphocyte-rich fraction was not measured in this study, 
the percentage of null lymphocytes could not be calculated. 
Thus,. in calculating absolute T and B cell numbers it was 
assumed that all the lymphocytes present in the lymphocyte-
rich fraction reacted with either the T or B cell marker. 
For example, absolute T .cells were calculated as: 
% RFC % RFC x absolute lymphocyte count + % srg-bearing cells 
where 
-RFC = rosette-forming cells (T cells) 
sig-bearing cells = surface immunoglobulin-bearing 
cells (B cells) 
The absolute lymphocyte count was calcul_ated from. total and . - . I 
dif.feren ti al white blood cell counts. 
Erythrocyte Rosette Assay 
T cells were assayed by rosette formation with dextran-
treated sheep erythrocytes by a method similar to that 
described by Binns (1978). An al-iquot of 0.1 ml of lympho-
cyte suspension (1 x 106 c'ells) was added to O. 2 ml of 1% 
SRBC in 6% dextran (m.w. = 150,000) 1 in a 1 ml conical 
l Dextraven. · 150_, Fi sons Lim. , Holmes Chapel, Cheshire, 
U.K. 
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centrifuge tube, mixed and incubated at 37°C for 10 minutes. 
The suspension was then centrifuged at 200 x g for 5 minutes 
at room temperature and incubated for about 16 hours at 4°C. 
Cells were resuspended by gently rocking the tube, and a 
drop of suspension, was placed on a slide under a coverslip. 
Two hundred lymphocytes were counted by light microscopy and 
the percentage of RFC (defined as bearing 3 or more ad-
herent RBC) was calculated. Ten independent estimates of the 
percen,tage of RFC from a single blood sample had a range of 
59-67, a mean of 63 and a standard deviation of 2.9. Rosette-
forming cells are illustrated in Figure 1. 
Quantitation of Immunoglobulin-
Bearing Cells 
Surface membrane immunoglobulin-bearing lymphocytes 
(B cells) were identified by the method described by Paul 
et al. (1979). An aliquot of 0.1 ml of lymphocyte suspension 
(1 x 10 6 cells) was placed in a 1 ml conical centrifuge 
,tube, which was then filled with PBS containing 0.2% sodium 
azide and 1% bovine serum albumin, and centrifuged at 800 x 
g for 2 minutes. The supernatant was removed and the cells 
were resuspended in 50 µl of a 1:10 dilution of fluorescein-
conjugated rabbit anti-porcine IgG (heavy and light chain 
specificity), 1 then incubated at 4°C for 30 minutes. After 
1Lot 10432, Cappel Laboratories Inc., Cochranville, 
,Pennsylvania. 
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Figure 1. Rosette-forming cells in lymphocyte-rich 
fraction (x 500) : (a) Rosette-forming 
cell, (b) Nonrosette-forming cell 
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incubation, the cells were washed 3 times with PBS containing 
sodium azide and bovine serum albumin, by centrifugation at 
200 x g for 2 minutes. Cell suspensions were then examined 
by alternating phase and fluorescent microscopy. The per-
centage of cells positive for slg was determined after 
·counting 200 cells. Ten independent estimates of the per-
centage of sig-bearing cells from a single blood sampie 
had a range of 26-33; a mean of 30 and a standard deviation 
of 2.4. 
Histopathology 
Thymus, spleen and.submandibular lymph nodes were 
fixed in formalin, sectioned and stained with hematoxylin 
and eosin using standard procedures. The sections were 
examined under light microscopy and various parameters 
quantitated; The concentrations of lymphocytes in the 
thymic medulla, lymphoid follicles and periarteriolar 
lymphoid sheath of the spleen, and the lymphoid follicles 
and paracortex of lymph nodes were calculated. Lymphocyte 
concentrations were assessed by randomly selecting 5 high-
power fields from each section and counting the number of 
cells in a designated area of the field. The number of 
lymphoid follicles per low-power field of the spleen was 
caiculated by taking the mean of the counts for 5 fields. 
The thickness of the cortex of the thymus was measured from 
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photomicrographs of 50 x magnification; 5 measurements for 
each animal were averaged. Thus the histological values 
obtained were not absolute counts, but purely for comparison 
of CY~treated and control tissues. 
Statistical Analysis 
'.{'he Stud.ent' s t test was used to determine the statistical 
sign"ificance of differences between the means of treated and 
control groups of animals for leukocyte counts, T and B 
lymphocyte counts and histopathological data. 
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RESULTS 
Determination of a Nonlethal Immunosuppressive 
Dose of Cyclophosphamide 
Experiments 1 to 4 were carried out in order to deter-
mine a CY dosage schedule which.caused immune suppression 
without mortality in the pig. Leukocyte counts were used 
as an easily measured indicator of CY' s effect on the .anl.mal; 
it was assumed that CY could not cause immune suppression 
in the absence of lymphopenia. The antibody response to 
specific antigens was determined in order to assess the 
effect of CY on the humoral immune system. Thus, the 
parameters examined in seeking an appropriate dosage 
regimen were leukocyte counts, antibody response. to SRBC 
qr PPV, and mortality. The results of Experiments 1 to 4, 
with respect to these parameters, are summarized in Table ~. 
In Experiments l to 4 blood was collected for white 
cell counts and titration of antibodies to the relevant 
antigen on day 0 (the day of commencement of CY treatment) 
and every 2 days.until the termination of the experiment. 
Experiment 1 
One-week-old gnotobiotic Yorkshire pigs were used. All 
CY treatments were administered as a single injection on 
day 0. Three pigs received 25 mg/kg of CY, 3 pigs received 
50 mg/kg of CY, 3 pigs received 75 mg/kg· of CY and 3 
Table 3. Summary of results obtained in the determination of an irnmunosuppressive 
but nonlethal dose of CY 
Age Treatment Number % 
Suppression 
Experiment (weeks) (mg/kg CY) of Survival Leukopenia of antibody pigs :tesEonse 
1 1 25 3 100 N A a,b • .b 
50 3 100 + N.A.b 
100 3 0 c N.A. N.A. 
2 1 50 3 100 + 
75 3 67 + +· 
100 3 .0 
c + N.A. 
3 6 50 + 20 x 2d 5 100 + + 
75 4 100 + 
4 3d 10 20 x 4 100 + + 
30 x 3d 8. 100 + + 
.50 3d 4 25 c x + N.A. 
aN.A. - not applicable. 
bNeither control nor treated animals responded to antigen inoculation. 
cThese pigs did not survive long enough for the appropriate criteria to be 
determined. 
dAll multiple dosages were administered as 3 injections, each 2 days apart. 
,.,. 
C.l1 
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pigs served as untreated controls. All pigs were inoculated 
with SRBC on day O. The experiment was terminated on day 
16. 
All the pigs treated with 25 mg/kg showed neutropenia 
on days 4 and 6, but there was no significant depression of 
lymphocyte or total leukocyte counts. The pigs which re-
ceived 50 mg/kg had significantly depressed total leukocytes, 
neutrophils and lymphocytes on days 4, 6 and 8. All animals 
treated with 100 mg/kg of CY died on day 2. The effect of 
CY on the antibody response to SRBC could not be assessed 
since none of the animals, including controls, showed any 
response whatsoever. 
Experiment 2 
One-week-old naturally farrowed Yorkshire pigs were 
used. The different CY treatments were single injections 
of 50 mg/kg, 75 mg/kg and 100 mg/kg, administered on day 0. 
Three pigs were assigned to each CY treatment group, and 3 
pigs were used as untreated controls. All animals were 
inoculated with SRBC on day 0, and white blood cell counts 
and antibody titers were followed until day 16. 
The animals which were treated with 50 mg/kg and 
75 .mg/kg of CY all had depressed lymphocyte counts on days 
2 and 4, and depressed total leukocyte and ·neutrophil counts 
on days 4 and 6. One of the animals treated with 75 mg/kg 
and all of the animals which received 100 mg/kg died within 
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4 days. Control animals and those treated with 50 mg/kg 
responded to SRBC on day 6. The animals treated with 75 
mg/kg did not respond at all; however, the significance of 
this is questionable since the control titers only rose from 
<l (no hemagglutination by undiluted serum) to 4. 
Experiment 3 
In Experiment 3, six-week-old naturally farrowed 
Yorkshire pigs were used. Since the control response to 
SRBC in the previous experiments was so poor, it was 
decided to use as the antigen inactivated PPV, which usually 
evokes a higher antibody titer (Mengeling et al., 1979). 
Thus· PPV-free animals were used in this experiment. Also, 
. since in Experiment 2 suppression of antibody formation was 
only obtained with a dose that killed one animal, it was 
de~ided to attempt a schedule of multiple nontoxic doses. 
Five pigs received 50 mg/kg of CY on day 0 then 20 
mg/kg on each of days 2 and 4. Four pigs received 75 mg/kg 
of CY on day 0 and there were 5 untreated controls. In-
activated PPV vaccine was administered to all animals on 
day O. The experiment was terminated on day 14. No animals 
die·d in this experiment. 
_Lymphopertia and neutropenia were seen in both CY 
treatment groups on days 4 and 6. Control animals and 
animals treated with 75 mg/kg had responded to PPV vaccine 
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by day 6, whereas the animals treated with the multiple 
dosage did not respond until day 8. Peak titers of CY-
treated animals were similar to those of controls. All the 
CY-treated animals appeared depressed. until about day 10; 
they also developed subcutaneous abscesses and cellulitis 
in the region of bleeding and injection sites. 
Experiment 4 
Ten-week-old naturally farrowed Yorkshire pigs were 
used. Since no PPV-free pigs were available, the antibody 
response to SRBC was examined; it was thought that ten-
week-old pigs would respond better to SRBC than the im-
munologically immature one-week-old pigs used in Experiments 
1 and 2. Since the antibody response was only delayed for 
2 days by the multiple CY administrations used in Experiment 
3, it was felt that better immune suppression could probably 
be obtained. Thus, in Experiment 4, three different multiple 
dosage regimens.were examined. In this experiment all the 
CY-treated and control pigs received broad-spectrum anti-
biotics to prevent the bacterial infections seen in the pigs 
in Experiment 3. 
Four pigs received 3 injections of 20 mg/kg of CY, 8 
pigs received 3 injections of 30 mg/kg of CY, 4 pigs re-
ceived 3 injections of 50 mg/kg of CY and 4 pigs served as 
untreated controls. Cyclophosphamide injections were 
administered on days 0, 2 and 4. Sheep red blood cells were 
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administered on day 0. The experiment ended on day 10 .. The 
schedule involving repeated injections of 30 mg/kg of CY 
was selected as the one to be used in further experiments1 
therefore, the results for animals which received this treat-
ment will be presented in detail. 
All CY treatment regj,mens caused a transient depletion 
of total leukocytes., neutrophils and lymphocytes. In animals 
which received 30 mg/kg injections of CY the maximum de-
pression of total leukocytes (Figure 2), neutrophils (Figure 
3)and lymphocytes (Figure 4) was seen on days 4 and 6, at 
which point lymphocyte counts were lowered by more than 60% 
and neutrophils were almost absent from peripheral blood. 
Total leukocyte counts of these pigs ~ere significantly 
(p<0.01) lower than those of controls on days 4, 6 and 8. 
Neutrophil counts were significantly depressed on days 4 
and 6, and lymphocyte counts were significantly lowered on 
days 2, 4, 6.and 8. In animals treated with 20 mg/kg in-
jections, the lymphocyte count was depressed by 33% on day 
6 and neutrophils were depressed by 90% on days 4 and 6. 
Recovery of both cell types had occurred by day 8. Three 
of the 4 animals which received 50 mg/kg injections of CY 
died on days 4, 8 and 10. The antibody response to SRBC 
was suppressed in animals which received 20 mg/kg and 30 
mg/kg injections of CY, but the suppression lasted longer 
in' the 30 mg/kg group. Control animals had mounted a 
Figure 2. Total peripheral blood leukocyte counts of controls and of animals 
which received three 30 mg/kg injections of CY (Experiment 4). Points 
represent mean + standard deviation 

Figure 3. Peripheral blood neutrophil counts of controls and of animals which 
received three 30 mg/kg injections of CY (Experiment 4). Points 
represent mean + standard deviation 

Figure 4. Peripheral blood lymphocyte counts of controls and of animals which 
received three 30 mg/kg injections of CY (Experiment 4). Points repre-
sent mean + standard deviation 
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detectable antibody response by 4 days after erythrocyte 
administration (Figure 5). Animals treated with 30 mg/kg 
injections of CY showed no detectable response until day 10 
(6 days.after the final CY treatment) and animals treated 
with 20 mg/kg injections had detectable titers on day 8. 
Some of the animals receiving the two lower dosages appeared 
depressed from day 1 until about day 8. No evidence of 
bacterial infections or adverse gastroenteric effects were 
seen. 
Further Investigation of the Effects of an 
Immunosuppressive Dose of Cyclophosphamide 
in the Pig - Experiment 5 
Since in Experiment 4 the best immune suppression with-
out mortality was obtained with repeated injections of 30 
mg/kg of CY, this regimen was used in Experiment 5 to in-
vestigate further the effect of CY on the immune system of 
the pig. In this experiment one litter of ten-week-old 
Yorkshire pigs and two litters of ten-week-old Berkshire 
pigs were used. Equal numbers of pigs from each litter were 
assigned to each treatment. 
Experimental design 
Eight pigs received 3 CY treatments of 30 mg/kg on days 
O, 2 and 4 (Treatment 1), 8 pigs received 6 CY treatments 
at 2-day intervals from day 0 (Treatment 2) and 8 pigs 
Figure 5. Antibody response. to sheep erythrocytes administered on day O, in 
controls and in animals which received three 30 mg/kg injections 
of CY (Experiment 4). Points represent mean+ standard deviation 
of the loge of the antibody titer 
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served as untreated controls. At various intervals after 
the first treatment, total and differential leukocyte counts 
were carried out.on peripheral blood. Two animals in Treat-
ment l were killed on each of days 6, 8, and 13 and 2 ani-
mals in Treatment 2 were killed on each of days 13, 14, 
and 18. Two control animals were sacrificed on each of 
days 6, 13, and 18 and those killed on days 6 and 13 were 
used as controls for the CY-treated animals killed on days 
8 and 14, respectively. The lymphoid tissues from the 
sacrificed animals were processed for histological examina-
tion. Two pigs from each treatment group, together with 
2_controls, were inoculated with SRBC on day 0 in order to 
monitor the antibody response. T and B cell counts were 
nqt carried out on these animals, because it was thought 
that immunization with SRBC may have interfered with the 
results of the T cell rosette test. 
Leukocyte counts 
The leukocyte suppression in animals in Treatment l 
was similar to that 'seen in animals which received the 
same treatment in Experiment 4. Total leukocyte (Figure 6) 
and neutrophil (Figure 7) counts were significantly de-
pressed on days 4; 6 and 8, whereas lymphocyte counts 
(Figure 8) were only significantly depleted on days 6 and 
8. Recovery of all cell types was apparent on day 8. Total 
leukocyte (Figur.e 6), neutrophil (Figure 7) and lymphocyte 
Figure 6. Total peripheral blood leukocyte counts of controls, of animals 
treated 3 times with CY (Experiment 5, Treatment 1) and of animals 
treated 6 times with CY (Experiment 5, Treatment 2). Points 
represent-mean + standard deviation 
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Figure 7. Peripheral blood neutrophil counts of controls, of animals treated 3 
times with CY (Experiment 5, Treatment 1) and of animals treated 6 
times with CY (Experiment 5, Treatment 2). Points represent mean 
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counts (Figure 8) for the animals in Treatment 2 followed 
the same pattern as for those in Treatment 1 until day 6 
and then continued to decrease slightly until day 13. Re-
covery of all cell types was evident on day 18, when counts 
were no longer significantly depressed. The numbers of 
monocytes in peripheral blood are shown in Table 4. Mono-
cyte counts in CY-treated animals were depressed following 
CY treatment, however no significance can be attached to 
this because control counts showed an almost three-fold 
day to day variation. 
T and B Lymphocytes in peripheral blood· 
The percentages of T lymphocytes in the lymphocyte-rich 
fraction were not affected by CY treatment (Table 5). How-
ever, CY caused a greater than 50% depletion of absolute 
T cell numbers (Figure 9). In animals which received 
Treatment 1, this depletion was only significant (p<0.01) 
on day 6, and a gradual increase in T cell numbers occurred 
after this point. In animals in Treatment 2, the depression 
of absolute T cell counts was significant from day 6 to 
day 13. 
Cyclophosphamide caused a marked depression of both 
B.cell percentages (Table 6) and absolute B cell counts 
(Figure 10). In the animals in Treatment 1, B cell per-
centages were significantly (p<0.01) lower than controls 
Table 4. - Monocyte counts· in peripheral blood -Of CY-treated and control animals 
Control Treatment 1 b. Treatment 2 c 
Day n monocytes/ n monocytes/ n monocytes/ 
cu mm a cu mm cu mm 
0 6 534 + 187 4 796 + 220 4 1,134 + 475 - -
4 6 996 + 365 . 4 59 + 55 4 122 + 133 - - -
6 6 554 + 237 4 286. + 76 4 293 + 174 - - -
8 4 .995 + 320 4 767 + 484 4 319 + 258 - - -
13 4 356 + 101 2 788 + 336 4 252 .+ 168 -
18 2 659 + 40 2 447 + 173 - -
"' ..., 
aThe values given represent the mean ± standard deviation of values from n 
animals. 
b . 
Animals which received 3 CY treatments (on days O, 2 and 4) . 
c . Animals which received 6 CY treatments (on days 0, 2, 4, 6, 8 and 10). 
-------~- ----
Table 5. Effect of CY on T cell percentages 
Control Treatment -}> Treatment 2c 
Day n % T n % T n % T 
cells a cells cells 
0 6 62 •. l + 9.3 4 74.3 + 5.3 4 65.8 + 3.9 - - -
4 6 61.5 + 6.2 4 70.8 + 5.2 4 68.3 + 6.6 - - -
6 6 60.5 + 4.0 4 66.8 + 9.9 4 65.0 +13.1 -
8 4 54.0 + 5.2 4 62.0 + 9.7 4 66.0 + 5.4 - - -
13 4 57.3 + 6.1 2 57.5 + 0.7 4 54.0 + 1. 9 - - -
18 2 53.0 + 4.2 2 58.5 + 2.1 - -
"' ro
a 
expressed as percentage of cells in the lymphocyte-Percentage of T cells 
rich fraction which form rosettes. The values given represent the mean + 
standard deviation of values from n animals. 
b . 1 Anima s which received 3 CY treatments (on days O, 2 and 4) . 
cAnimals which received 6 CY treatments (on days O, 2, 4, 6, 8 and 10) . 
Figure 9. Absolute T lymphocyte counts in 
animals treated 3 times with CY 
6 times with CY (Treatment 2). 
deviation 
peripheral blood of controls, of 
(Treatment 1) and of animals treated 
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Table 6. E.ffect of CY on B cell percentages 
Control Treatment lb Treatment 2c 
Day n % B n % B n % B 
cells a eel.ls cells 
0 6 24.2 + 5.6 4 17.3 + 6.7 4 24 0 5 + 3.1 - - -
4 6 24.2 + 6.2 4 5.5 + 1.7 4 9.5 + 4.7 
6 6 21. 0 + 5.1 4 3.3 + 1.3 4 5.3 :t 2.1 -
8 4 25.5 + 6.1 4 5.3 + 1.7 4 3.0 + 2.4 - - -
13. 4 23.0 + 7.0 2 12.5 + 3.5 4 1.8 + 1.0 - - -
18 2 28.0 + 11.3 2 12.0 + 8.5 __, - I-' 
aPercentage of B cells expressed as percentage of cells in the lymphocyte-
rich fraction which are sig-positive. The values given represent the mean + 
standard deviation of values from n animals. 
b . 1 Anima s which received 3 CY treatments (on days O, 2 and 4) . 
c . . 1 Anima s which received 6 CY treatments (on days 0, 2, 4, 6, 8 and 10) . 
Figure 10. Absolute B lymphocyte counts- in peripheral blood of controls, of 
animals treated 3 times with CY (Treatment 1) and of animals 
treated 6 times with CY (Treatment 2). Points represent mean+ 
standard deviation 
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from day 4 until day 8 (4 days after the last treatment). 
In this treatment group, absolute B cell counts were sig-
nificantly below controls from day 2 to day 13 (9 days after 
the last CY treatment), although numbers had started to 
increase by day 8. The animals in Treatment 2 showed a 
simila)'." response, with significant depress.ion of B cell 
percentages until 3 days after the final treatment and 
depression of absolute B cell counts until 8 days after 
the final treatment. In both treatment groups there was a 
greater than 90% depletion of B lymphocytes at the point 
of maximum depression. 
Antibody .response to sheep erythrocytes 
As in Experiment 4, control animals had detectable 
hemagglutinins in their serum by day 4 whereas animals in 
Treatment 1 had no detectable antibody titer until day 10 
(Figure 11). The animals in Treatment 2 did not respond 
until day 18 (Figure 11). 
Histological examination of lymphoid tissues 
In the thymus of CY-treated animals there was a marked 
loss of distinction between the cortex and m~dulla, with 
thinning of the cortex due. to lymphocyte depletion (Figures 
12(a) and (b)). Table 7 shows the relative values for the 
thickness of the cortex in CY-treated and control animals. 
Cortical thickness was significantly reduced on day 6 (2 days 
Figure 11. Antibody response to sheep erythrocytes administered on day O, in 
controls, in animals treated 3 times with CY (Experiment 5, 
Treatment 1) and of animals treated 6 times with CY (Experiment 
5, Treatment 2). Points represent mean+ standard deviation 
of the loge of the antibody titer 
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Figure 12. Effect of CY on morphology of the thymus. 
H & Estain; x"60: (a) Thymus of control 
pig sacrificed on day 13, (b) Thymus of a 
pig treated 6 times with CY (Treatment 2) 
and sacrificed on day 13; showing a depletion 
of cortical lymphocytes and loss of distinc-
tion between cortex and medulla 
I 
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Table 7. Effect of CY on cortical thickness and medullary 
lymphocyte concentration in the thymus 
Day 
killed Control 
c d Thickness of cortex ' 
6 1.52 + 0.37 
8 
13 1.70 + 0.16 
14 
18 1.53 + 0.25 
Lymphocyte concentration 
6 26.4 + 1.1 
8 
13 23.9 + 0.4 
14 
18 24.3 + 2.5 
in 
Treatment la 
0.34 + 0.11* 
0.95 + 0.07 
1.15 + 0.07 
medullad,e 
21.1 + 1.8 
20.8 + 0.4 
22.3 + 3.2 
b Treatment 2 
0.10 + 0.07** 
0.70 + 0.42 
0,88 + 1.17 
13.7 + 0.2** 
18.8 + 3.9 
19.0 + 7.8 
aAnimals which received 3 CY treatments (on days O, 2 
and 4) • 
bAnimals which received 6 CY treatments (on days 0, 2, 
4, 6, 8 and 10). 
ccortical thickness was measured in centimeters from 
photC>micrograp1ls . -o_f ?OX magnification, therefore the values 
given are relative.· 
dThe values represent the mean + standard deviation of 
values from 2 animals. -
e -
Lymphocyte concentration expressed as the number of 
lymphocytes in a designated area of a high power field. 
* Significantly different from control value (p<0.05). 
** 
Significantly different from control value (p<O. 01) ·. 
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after the final CY treatment) in animals in Treatment l and 
on day 13 (3 days after the final treatment) in animals in 
Treatment 2. In both groups cortical lymphocyte repopu-
lation had started to occur by 4 days after the final treat-
ment, when values for cortical thickness were not signifi-
cantly below control values. The concentration of lympho-
cytes in the medulla of the thymus was not affected by 
Treatment l; it was significantly reduced on day 13 in 
the animals in Treatment 2, but recovery was evident on day 
14 (Table 7). The standard deviations for cortical thick-
ness and medullary lymphocyte concentration values of 
animals in Treatment 2 on day 18 are very large. This is 
because the thymus of one of the two animals killed on this 
day was still markedly atrophic whereas the thymus of the 
other was indistinguishable from normal. 
Table 8 shows the changes in lymphoid areas of the 
spleen in CY-treated animals. Treatment l depleted the 
number of lymphocytes in lymphoid follicles on days 6 and 
8 (Figures 13(a) and (b)) without significantly decreasing 
the number of follicles; there was no effect on lymphocyte 
concentration. in the periarteriolar sheaths. In Treatment 
2 depression of both follicle numbers and follicle lympho-
cyte concentrations was seen on days 13 and 14; values for 
day 18 were not significantly below controls. The concen-
tration of lymphocytes in periarteriolar sheaths from animals 
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Table 8. Effect of CY on the number of splenic lymphoid 
follicles and lymphocyte concentration in lymphoid 
follicles and periarteriolar lymphoid sheaths in 
the spleen 
Day 
killed 
N.umber 
6 
8 
.Control 
. . c d 
of follicles ' 
4.1 + 1 •. 3 
13 4.9 + 0.4 
14 
18 4.0 + 1.4 
Lymphocyte concentration 
6 22.l + 2.1 
8 
13 
14 
18 
21.8 + 0.8 
23.0 + 1.4 
Lymphocyte concentration 
6 23.6 + 0.8 
8 
13 .22.5 + 0.7 
14 
18 25.3 + 1.1 
Treatment la 
1.2 + 0.0 
1.0 + 0.6 
2.1 + 0.4 
in fo1liclesd,e 
9.4 + 1.4* 
11.0 + 1.4* 
22.0 + 0.7 
Treatment 2b 
0.2 + 0.2** 
0.7 + 1.0* 
1.4 + 2.0 
3.2 + 4.5* 
10 • .5 + 0.7** 
6.0 + 8.5 
in periarteriolar sheathsd,e 
21.5 + 1.5 
21.5 + 2.1 -
2B.3 ::t 2.5 13.8 +· 0.6** 
20.0 + 2.1 -
21.5 + 0.7 
aAnimals which received 3 CY treatments (on days 0, 2 
and 4) . 
bAnimals which received 6 CY treatments (on days O, 2, 
. 4, 6, 8 and 10) • 
cNumber of follicles per low power field. 
dThe values represent the mean + standard deviation of 
values from .2 animals. 
eLymphbcyte concentration expressed as the number of 
lymphocytes in·a designated area of a high power field. 
·* . . 
Significantly .~ifferent from control value (p<0.05). 
** 
Significantly different from cor;trol value (p<O,Ol). 
Figure 13. Effect of CY on morphology of the spleen. 
H & E stain; x 260: (a) Spleen of control 
pig sacrificed on day 6, showing a lymphoid 
follicle (outlined by arrows), (b) Spleen of 
a pig treated 3 times with CY (Treatment 1) 
and sacrificed on day 6, showing depletion 
of lymphocytes from a lymphoid follicle 
(outlined by arrows) 
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in Treatment 2 was depressed on day 13 but had already re-
turned to normal by day 14. 
CY-induced changes in the submandibular lymph nodes 
(Table 9) were less marked than in the spleen and thymus. 
Treatment 1 resulted in an initial depletion of lympho-
cytes in lymphoid follicles with recovery by day 13; no 
effect on the lymphocyte concentration in paracortical 
areas was seen. Treatment 2 caused a depression of the 
follicle lymphocyte concentration which was still apparent 
on day 18; paracortical areas were also depleted of lympho-
cytes but repopulation had occurred by day 14. 
Table 9. Effect of CY on the concentration of lymphocytes 
in the lymphoid follicles and paracortical areas 
of the submandibular lymph node 
Day 
killed Control 
. a 
Treatment 1 Treatment 2b 
Lymphocyte concentration in folliclesc,d 
6 21.1 + 0 •. 4 10.5 + 3.3* 
8 9.5 + 0.7** 
20.5 + 0.3 5.3 + 1.0** 
aAnimals which received 3 CY treatments (on days 0, 2 
and 4) • 
bAnimals which received 6 CY treatments (on days O, 2, 
4 , 6 , 8 and .l 0 ) • 
cLymphocyte concentration expressed as the number of 
lymphocytes in a designated area of a high power field. 
dThe values represent the mean + standard deviation of 
values from 2 animals. 
* Significantly different from control value (p<0.05). 
** 
Significantly different from control value (p<0.01). 
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Table 9 (Continued) 
Control Treatment l Treatment 2 
Lymphocyte concentration in follicles (cont.) 
14 9 .. 6 + 0;7** 
18 21.2 + 0.5 13.4 + 2.1* -
Lymphocyte concentration in paracortical areasc,d 
6 29~5 + 3.5 34.0 + 1. 4 -
8 33.0 + 2.1 
13 35.5 + 0.7 30.l + 2.9 20.5 + 0.7** - -
14 21.4 + 4.6 
18 30.2 + 2.1 32.5 + 3.4 -
Figure 14. Effect of CY on lymph node·morphology. 
H & E stain; x 260: (a) Submandibular lymph 
node of control pig sacrificed on day 6, 
showing a lymphoid follicle, (b) Sub-
mandibular lymph node of a pig treated 3 
times with CY (Treatment 1) and sacrificed 
on day 6, showing depletion of lymphocytes 
from the center of a lymphoid follicle 
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DISCUSSION 
It was demonstrated in Experiments 1 and 2 that single 
injections of 100 mg/kg of CY cause 100% mortality within 4 
days in one-week~old pigs. Anderson et al. (1974) also 
used single injections of 100 mg/kg in one-week-old pigs;· 
in their paper no.me'ntion is made of mortality, however, all 
pigs were sacrificed 4 days after treatment.. This dose is 
well below' the dose of 600 mg/kg which Kovacs and Steinberg 
(1972) r.eported to .cause rapid death in mice. Older pigs 
may be ab!e to survive a higher dose than one-week-old 
pigs; in Experiment 4, however, 3 doses of 50 mg/kg adminis-
tered every 2 days were lethal for ten-week-old pigs. There-
f9re this age group appears to be as susceptible as one-
~eek-old pigs. The therapeutic index for single doses of 
CY in pigs could not be calculated because detailed dose-
response experiments·were not carried out; however, in 
Experiment 2 the antibody response was only suppressed at 
a dose which killed one of three pigs. This is different 
from the situation in mice, in which antibody formation was 
~liminated by.50 mg/kg of CY whereas toxicity only occurred 
at single doses above 200 mg/kg (Berenbaum and Brown, 1964). 
It is possible tJ:iat lower single doses would have caused 
suppression of the antibody response in pigs if the antigen 
had b.een administered 2 days before CY, as in the work,_ of 
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Berenbaum and Brown (1964). 
·A nonlethal multiple CY dosage regimen, in contrast, 
was shown to cause immune suppression in ten-week-old pigs. 
' 
Multiple injections of 30 mg/kg, administered at two-day 
intervals, prevented the formation of detectable anti-
bodies to sheep erythrocytes un.til several days after the 
last injection, whether 3 or 6 doses were used. Thus, 
the duration of ·immune suppression can be varied according 
to the number of injections· used. 
The depression of total blood leukocyte counts was 
in agreement with previous work in the pig (Anderson et al., 
1974). The total leukocyte depletion was contributed to 
by the depletion of both lymphocytes and neutrophils. 
Cyclophosphamide also appeared to cause a depression of 
circulating monocyte counts;. however, control values were 
too variable to place any significance on these counts. 
The variability was probably due to the low numbers of 
monocytes in blood smears. The intravascular half-life 
of neutrophils is approximate·lY 6 hours, and the bone 
marrow is considered to contain a neutrophil reserve of 
approximately 4 to 8 days' supply (Schalm et al._, 1975). 
Thus, the almost complete lack of circulating neutrophils 
within 4 days of initial treatment, and commencement of 
recovery within 4 ,days of c.essation of treatment, can be 
explained as the prevention of mitotic activity- of myeloblasts 
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by CY. 
The kinetics of CY-induced depletion of lymphocytes 
in blood and lymphoid tissues are more difficult to explain. 
Cyclophosphamide could deplete lymphocytes by causing death 
or prevention of mitosis in lymphocytes, or sequestration 
of lymphocytes in nonlymphciid tissues. Turk and Poulter 
(1972b) showed that the depletion of lymphocytes in lymphoid 
tissues of mice was not due to localization in other 
9rgans, therefore it is unlikely that this mechanism 
plays a part in lymphocyte depletion in pigs. Turk and 
Poulter (1972a) attributed the effect of CY on murine 
lymphoid tissues to a purely mitostatic effect. The pre-
vention of lymphocyte mitosis by CY is well-documented in 
mice (Turk and Poulter, 1972b) and calves (Wagner·et al., 1976) 
thus this mechanism is probably important in the present 
study. In contrast, Petrov et al. (1971) demonstrated that 
CY treatment of mice caused a greater suppression of graft 
versus host reactions than of hemopoiesis, and concluded 
that CY has a direct toxic effect on lymphocytes, as well as 
a mitostatic effect. Under the conditions of the present 
study it seems likely that CY has a lymphotoxic effect since 
·in Experiment 4 there was a 60% depletion of circulating 
lymphocytes by 4 days after the initial treatment, and even 
the short-lived B lymphocytes are reported to have an average 
lifespan of 5 weeks (Sprent and B·asten, 1973). This con-
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clusion is supported by the data showing that circulating 
T cell numbers were depressed (Figure 9). The average life-
span of circulating.T lymphocytes is reportedly 4 to 6 months 
(Sprent and Basten, 1973), therefore a 50% depletion within 
6 days of commencement of treatment must be partly due to a 
direct toxic effect on these cells. Thus, in the present 
study CY probably caused both death and. mitostasis in 
lymphocytes. 
Recovery of lymphocyte numbers in blood and lymphoid 
tissues was apparent within 4 days of cessation of CY 
administration in the animals which received Treatment 1. 
This rapid recovery could be explained by cyclophosphamide's 
mitostatic effect;" however, it has been argued that CY 
also has a lymphotoxic effect in the present study. This 
lymphotoxic effect must mainly involve a mature, noridividing 
cell population, since if CY destroyed a significant pro-
portion of the dividing precursor popul~tion, a much slower 
recovery would be expected. 
As discussed in Materials and Methods, the lymphocyte-
rich. fraction used in this study to determine T and B cell 
numbers contains a certain percentage of contaminating. cells. 
It seems likely that in the present study this percentage 
is relatively low since in controls the percentages of 
lymphocytes reacting with T cell and B cell markers usually 
added up to about 85%. This figure is similar.to that 
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obtained by Salmon (1979) , who estimated that 2 to 7% of the 
lymphocyte-rich fraction from pigs were contaminating cells, 
the remainder being null lymphocytes, whereas in another 
study in pigs, 26%' of cells were contaminants arid only· 56% of 
cells reacted with the T and B cell markers (Shimizu et al., 1976). 
since CY treatment caused a decrease in the percentage 
of sig-positive cells, without affecting the percentage of 
RFC, either the percentage of null lymphocytes or the per~ 
centage of contaminating nonlymphoid cells increased. It 
is not known which cell percentage increased since the per-
centage of contaminating cells was not determined. Also, 
total monocyte counts in controls were too variable to say 
whether monocyte numbers were affected by CY treatment, and 
thus whether they could have .contributed to an increase in 
the percentage of cells not reacting with markers. It seems 
qµite possible that the percentage of null lymphocytes in-
creased, since Binns et al. (1977) demonstrated the existence 
in porcine blood of a cell population which neither formed 
rosettes with dextran-treated SRBC nor possessed sig, and 
was depleted by thymectomy. Perhaps CY spares this 
thymus-dependent null cell population. 
The percentage of null lymphocytes was not known, thus 
it was assumed in calculating absolute T and B cell counts 
that all lymphocytes were RFC or sig-positive. The absolute 
cell counts were not entirely accurate but this method of 
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calculation has the effect of underestimating rather than 
overestimating the CY-induced depression of absolute 
counts . For example,T cell counts in Treatment 2 were 
d d f 65 · 8 11 000 = 8 016 on day 0 to epresse ram 65 . 8 + 24 . 5 x , , 
66 . 0 6 !·~ . 0 x 4 , 000 = 3,826 on day 8 (i.e ., 52 % depletion), 
whereas if it had been assumed that all the cells which 
were not RFC or sig-positive were null lymphocytes, the 
depression would have been from 6{0~ x 11,000 = 7,238 to 
6
1
6
0·0° x 4 , 000 = 2,640 (i.e., 64% depletion) (see formula 
for absolute T cell counts in Materials and Methods). 
Despite these limitations, the T and B cell counts do 
provide some useful information. B cells were depleted by 
CY more than T cells, since B cell percentages were 
depressed and T cell percentages were not. Cyclophosphamide 
treatment did cause a depletion of circulating T cells, al-
though the absolute counts presented in this study probably 
underestimate the true magnitude of the depletion, and T 
cell counts returned to normal more rapidly than B cell 
counts. 
In contrast to the results of the present study, 
Anderson et al. (1974) showed that CY treatment of one-week-
old pigs decreased circulating B cell percentages and in-
creased circulating T cell percentages without affecting 
absolute T cell numbers. Several factors may account for 
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this difference in results. These workers used a single 
high CY dose. Also, they only carried out T cell counts 4 
days after CY treatment, that is, at a time when in the 
present study absolute T cell counts were not yet sig-
nificantly depressed. The T cell marker used by Anderson 
et al. was rosette formation with untreated SRBC, but Binns 
(1978) subsequently showed that the percentage bf porcine 
lymphocytes which formed rosettes was much higher with dextran-
treated SRBC than with untreated SRBC. Perhaps CY depletes 
a subpopulation of T cells which forms rosettes with dextran-
treated SRBC but pot untreated SRBC, and spares a subpopu-
lation which reacts with both. Thus, in the study of Anderson 
et al., absolute T cell counts of controls would not have 
included this CY-sensitive T cell subpopulation, and this 
would account for a lack of T cell depletion in CY-treated 
pigs. Evidence for the existence of a CY-insensitive T 
cell subpopulation has been produced by several other 
workers. Dumont (1974) showed that CY depleted only one of 
two murine T cell subpopulations which differed on the basis 
of electrophoretic mobility. Neta et al. (1977) showed that 
guinea pig thymus cells suppressed in vitro lymphoprolifera-
tive responses and that thymus cells from CY-treated guinea. 
pigs had an enhanced suppressive ability. The authors 
suggested that thymic suppressor cells are resistant to CY 
treatment and that their activity becomes more pronounced 
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with the depletion of other types of thymic cells. Glaser 
(1979) and Mitsuoka et al. (1979) attributed the CY-induced 
enhancement of tumor immunity in mice and delayed hyper-
se.nsi tivi ty in mice, respectively, to the elimination of 
suppressor T cells and the sparing of effector T cells. 
Thus probably at least one T cell subpopulation is 
resistant to CY treatment. 
The depletion of lymphocytes in lymphoid tissues by 
CY followed a pattern in the present study similar to that 
previously reported i.n pigs (Anderson et al., 1974), as well 
as in guinea pigs, mice (Turk ahd Poulter, 1972a) and chic-
kens (Lerman and Weidanz, 1970). The quantitative pathology 
carried out in the present study extends the descriptive 
work in pigs presented by Anderson et al. (1974) and con-
firmed that B cells are affected more thari T cells. Three 
or 6 injections of CY depleted lymphocytes from the cortex 
of the thymus and 6 injections caused a depletion of 
medullary lymphocytes. Lymphocyte depletion from the B-
dependent areas (lymphoid follicles) of the spleen lasted 
longer than the depletion from T-dependent areas (peri-
arteriolar lymphoid sheaths). Similarly, depletion of 
lymphoid follicles in lymph nodes was more persistent and 
more marked than depletion of paracortical. (T-dependent) 
areas. It is interesting to note that despite the "in-
verted" structure of the lymph node of the pig (McFarlin 
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and Binns, 1973), CY affects the B-dependent and T-dependent 
areas of pig lymph nodes in the same way as in other species. 
The preferential effect of CY on B cells in peripheral 
blood and lymphoid tissues is probably partly due to the 
more.rapid proliferation of B cells than of T cells, as 
suggested by Turk and Poulter (1972b). However, this may 
not be the sole reason since, as discussed previously, CY 
appears not only to affect dividing lymphocyte populations, 
but also nondividing lymphocytes. Thus, Bach's (1975) 
suggestion that the higher metabolic activity of B cells 
makes them more susceptible to the effect of CY is 
probably also important. T cell numbers probably return to 
normal more rapidly than B cell numbers because the B cell 
depletion is more dramatic than the T cell depletion. 
In the present study, the formation of antibodies to 
SRBC was suppressed in CY-treated pigs. The period during 
which antibody formation was suppressed correlated well 
with the time of maximum depression of circulating B cells; 
in animals in Treatment 1 absolute B cell counts started to 
increase on day 8 and antibodies to SRBC were detectable 
in serum on day 10. Thus the suppression of the humoral 
immune response could have been solely due to a lack of 
cells able to differentiate_into antibody-producing cells. 
Since SRBC is a T-dependent antigen (Douglas, 1978), how-
ever, the suppression of antibody formation could have been 
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partly due to the T cell depletion. Alternatively, since 
CY is known to suppress functions of T and B lymphocytes in 
other species, as witnessed by the depression of the 
in vitro lymphoblastogenic response to mitogens (Dumont, 
1974; Stockman et al., 1973), surviving lymphocytes may not 
be able to respond to antigen sensitization until after 
the CY-induced damage to DNA"has been repaired. This 
latter suggestion may explain why in animals treated with 
20 mg/kg injections of CY (Experiment 4), antibody formation 
was delayed, although lymphocyte counts were only depleted 
by 33%. 
In summary, the effect of CY on the immune system of 
the pig was similar to that seen in other sp~cies with 
respect to the parameters observed in this investigation. 
Cyclophosphamide caused immune suppression, characterized 
by depression of the antibody response and depletion of 
blood and tissue lymphocyte populations, with a preferential 
effect on B cells, although T cells were significantly 
affected. The ability of CY administered in a multiple 
dosage regimen to cause reproducible immune suppression, 
followed by rapid recovery after cessation of treatment, 
should make CY a useful research tool in the pig. 
Since in the present study CY caused a depletion of 
T cells, further investigations in this area could include 
examination of the effect of ·cy on in vivo and in vitro 
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functions of cell-mediated immunity in the pig, for instance 
delayed hypersensitivity and in vitro cytotoxicity by lympho-
cytes. Such experiments would aid in the use of CY to in-
vestigate the pathogenesis of infectious diseases in pigs. 
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SUMMARY 
The effects of cyclophosphamide (CY) on circulating 
leukocytes, lymphoid tissues and the antibody response of 
the pig were examined. It was found that single nonlethal 
doses of CY caused leukopenia but did not suppress the anti-
body response to specific antigens. It was necessary to use 
a multiple dosage regimen to obtain immune suppression without 
mortality. Ten-week-old pigs were treated with intraperi-
toneal injections of 30 mg/kg CY at 2-day intervals. Three 
CY injections caused a depression of total leukocytes, 
neutrophils and lymphocytes. Circulating B lymphocyte 
percentages were depleted by 80% and absolute B lymphocyte 
counts by 90%. Circulating T lymphocyte percentages were 
not affected by CY treatment, but absolute T cell counts were 
depressed by 50%. Lymphocytes were depleted from the cortex 
of the thymus and from the spleen and lymph nodes with a 
preferential effect on B-dependent areas. All these vari-
ables. were depressed for the duration of CY treatment and had 
started to return to normal by 4 days after the final treat-
ment. Formation of antibodies to sheep erythrocytes was 
suppressed in CY-treated pigs uritil 10 days after immuniza-
tion (6 days after the final CY treatment); control pigs 
showed a detectable response at 4 days after immunization. 
Six CY treatments prolonged the depression of all the above 
variables. 
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